CNS pharmaceutical compositions and methods of use
The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of the CNS active agent without changing its therapeutic efficacy/activity. The invention further encompasses a method of reducing CNS active agent side-effects. The method typically comprises oral administration of at least one CNS active agent to a patient at the conventionally accepted dose; and administration of at least two vagal neuromodulators to the patient so that at least one neuromodulator is administered or released from dosage form after the CNS active agent is administered and/or released.
1. A method of reducing a side-effect of a central nervous system (CNS) active agent, the method comprising:
administering at least one CNS active agent selected from the group consisting of a benzodiazepine, a muscle relaxant, and an anti-psychotic to a patient; and
administering at least two vagal neuromodulators to the patient in an amount sufficient to reduce a side-effect of the CNS active agent, wherein the at least two vagal neuromodulators comprise at least one mechanoreceptor stimulator and at least one adrenomimetic,
wherein the at least one mechanoreceptor stimulator and/or adrenomimetic is administered or released at least about 5 minutes after the CNS active agent is administered or released and the side-effect is selected from the group consisting of sedation, somnolence, and sleepiness.
2. The method of claim 1 , wherein the side-effect is somnolence.
3. The method of claim 1 , wherein the side-effect is sedation.
4. The method of claim 1 , wherein the mechanoreceptor stimulator is guaifenesin (GUA).
5. The method of claim 4 , wherein the GUA is released about 10 to about 20 minutes after the release of the CNS active agent.
6. The method of claim 1 , wherein the adrenomimetic is pseudoephedrine (PSE).
7. A method of reducing a side-effect of a central nervous system (CNS) active agent, the method comprising:
administering at least one CNS active agent selected from the group consisting of a benzodiazepine, a muscle relaxant, and an anti-psychotic to a patient; and
administering at least two vagal neuromodulators to the patient in an amount sufficient to reduce a side-effect of the CNS active agent, wherein the at least two vagal neuromodulators comprise at least one mechanoreceptor stimulator and at least one adrenomimetic to the patient,
wherein the at least one mechanoreceptor stimulator and at least one adrenomimetic are in an amount sufficient to reduce the side-effect associated with the CNS active agent and the side-effect is selected from the group consisting of sedation, somnolence, and sleepiness.
8. The method of claim 7 , wherein release or the administration of the mechanoreceptor stimulator is delayed.
9. The method of claim 7 , wherein the CNS active agent has a time to maximum concentration (Tmax) and the mechanoreceptor stimulator has a Tmax, and administration or release of mechanoreceptor stimulator is delayed for an amount of time being equal to the Tmax of the CNS active agent minus the Tmax of the mechanoreceptor stimulator plus about 5 to about 30 minutes.
10. The method of claim 7 , wherein the mechanoreceptor stimulator is selected from the group consisting of: mucomodulators and surfactants.
11. The method of claim 10 , wherein the mechanoreceptor stimulator is guaifenesin (GUA).
12. The method of claim 7 , wherein the adrenomimetic is pseudoephedrine (PSE).
13. The method of claim 11 , wherein the GUA is administered about 5 to about 30 minutes after administration of the CNS active agent.
14. The method of claim 7 , wherein the side-effect somnolence.
15. The method of claim 7 , wherein the side-effect is sedation.
16. The method of claim 7 , wherein the side-effect is reduced without reducing efficacy of the CNS active agent.